Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

2(33%)

Results Posted

67%(2 trials)

Terminated

1(17%)

Phase Distribution

Ph phase_1

67%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

4(66.7%)

Phase 2Efficacy & side effects

2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(3)

Terminated(1)

Detailed Status

Completed3

Terminated1

Recruiting1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 2

Trials by Phase

Phase 14 (66.7%)

Phase 22 (33.3%)

Trials by Status

terminated117%

recruiting117%

completed350%

active_not_recruiting117%

Recent Activity

2 active trials

Showing 5 of 6

recruitingphase_2

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

NCT05198830

active_not_recruitingphase_1

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

NCT02535312

completedphase_1

Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer

NCT02535325

terminatedphase_2

Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma

NCT02395692

completedphase_1

Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors

NCT00892385

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT05198830Phase 2

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Recruiting

NCT02535312Phase 1

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Active Not Recruiting

NCT02535325Phase 1

Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer

Completed

NCT02395692Phase 2

Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma

Terminated

NCT00892385Phase 1

Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors

Completed

NCT01658319Phase 1

Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies